SCHEMBL6764202

SCHEMBL6764202

CC(C)(C)Oc1ccc(Cl)c(C(F)(F)F)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.45
PPARG P37231 1/20 0.43
PPARA Q07869 1/20 0.43
HTR3E A5X5Y0 1/20 0.41
HTR3B O95264 1/20 0.41
HTR3A P46098 1/20 0.41
HTR3D Q70Z44 1/20 0.41
HTR3C Q8WXA8 1/20 0.41
KDR P35968 1/20 0.41
GPR84 Q9NQS5 1/20 0.41
RAPGEF4 Q8WZA2 1/20 0.41
NPFFR2 Q9Y5X5 1/20 0.40
HSD17B10 Q99714 1/20 0.39
NOTUM Q6P988 2/20 0.39
HSD11B1 P28845 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
AR P10275 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13945703 0.90 AR (0.47) IDO1KDRCA7CA9AR
SCHEMBL13945702 0.82 RAPGEF4 (0.54) KDRRAPGEF4CA1CA2CA7
SCHEMBL10709853 0.81 IDO1 (0.45) IDO1PPARGPPARAHTR3EHTR3B
SCHEMBL1043138 0.81 MAPT (0.52) IDO1PPARGPPARAHTR3EHTR3B
SCHEMBL29573736 0.81 MAPT (0.52) IDO1PPARGPPARAHTR3EHTR3B
SCHEMBL6764131 0.79 HTR2A (0.43) HSD11B1AR
SCHEMBL6764273 0.78 HSP90AA1 (0.48) LMNA
SCHEMBL13141644 0.78 GPR3 (0.42) MAPT
SCHEMBL13945707 0.77 KDR (0.72) KDRCA1CA2CA7CA9
SCHEMBL3923371 0.77 IDO1 (0.56) IDO1PPARGPPARAHTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8183238-B2 Bicyclic and tricyclic compounds as KAT II inhibitors PFIZER INC. (US) 2012-05-22 US disclosed
US-8183238-B2 Bicyclic and tricyclic compounds as KAT II inhibitors PFIZER INC. (US) 2012-05-22 US disclosed
US-20100324043-A1 Bicyclic And Tricyclic Compounds As KAT II Inhibitors PFIZER INC 2010-12-23 US disclosed
US-20100324043-A1 Bicyclic And Tricyclic Compounds As KAT II Inhibitors PFIZER INC 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324043-A1 Bicyclic And Tricyclic Compounds As KAT II Inhibitors KAT2A, KAT2B, KAT6B IDO1 2999/4885PPARG 2083/4885PPARA 3095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.